Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain...
CancerChronic Pain2 moreThe primary objective of this study is to describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of indication (neuropathic sequelae pains, morphine additional effect or morphine withdrawal, intensity, localisation…) and administration protocol (route, posology, duration, administration sequence, premedication). The secondary objectives are to evaluate in the context of cancer, the analgesic efficacy, the tolerance profile (biological and clinical toxicities) and the quality of life, including anxiety and depression. In addition, the described parameters will be evaluated as safety and efficacy predictive factors of the Ketamine in oncology.
Neuropathic Pain in Children: Multimodal Assessment and Diagnosis
Neuropathic PainChild1 moreSome children experience chronic pain that is related to damage or diseases that affect the nerves that send pain signals. This is known as neuropathic pain. This is not well understood and can be difficult to diagnose. It can often produce unusual feelings such as sensitivity of the skin to light touch. Neuropathic pain is often severe and difficult to treat, and can affect quality of life for the child and family. This study aims to better characterise the symptoms and signs, and impact of neuropathic pain in children.
Pregabalin Treatment and Prevention Post-herpetic Neuralgia
Herpetic NeuralgiaPregabalin is effective on herpetic neuralgia, but whether can prevention post-herpetic neuralgia still need to confirm.
Determination of the Antidepressant Duloxetine in Plasma to Improve the Knowledge of the Analgesic...
Neuropathic PainThe primary purpose of this protocol is to evaluate the lowest plasma concentration (ie before the daily taking dose of duloxetine) in patients relieved of at least 30% of their neuropathic pain with duloxetine treatment. The secondary purpose of this protocol is to determine plasmatic concentration peak (ie 6 hours after taking duloxetine) in patients relieved of at least 30% of their neuropathic pain with duloxetine treatment. Others secondary purposes are to evaluate the intensity of neuropathic pain, to assess the degree of pain relief and to evaluate the sensation of the global improvement experienced by the patient.
Duloxetine for PHN
Postherpetic NeuralgiaIn this study, the investigators aim to investigate the preventive efficacy of prophylactic oral duloxetine during acute herpes zoster on postherpetic neuralgia and its safety.
Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - a Prospective Study in 60 Patients...
Trigeminal NeuralgiaMultiple Sclerosis2 moreClinical characteristics, neuroanatomical findings and efficacy of medical and surgical treatment of symptomatic trigeminal neuralgia - a systematic prospective study of 60 consecutive patients
Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic...
Post Herpetic NeuralgiaStudy objective is to assess the safety and effectiveness of once- daily GRALISE in clinical practice
A Study of Efficacy and Safety of Qutenza in Patients With Post-operative Peripheral Neuropathic...
Post-operative Peripheral Neuropathic PainThe aim of this study is to monitor the effectiveness and used dosage of the 8% capsaicin patch in real-life clinical practice in the treatment of post-operative neuropathic pain.
Non-Interventional Study In Patients With Peripheral Or Central Neuropathic Pain Treated With Lyrica...
NeuralgiaThe purpose of this study is to obtain more data about efficacy and safety of the study drug Lyrica.
Injection of Subcutaneous Glucose 10% in Small Shots is Effective in the Treatment of Diabetic Neuropathic...
Painful Diabetic NeuropathyObservational cohort prospective study with the following of 100 patients of type 1 and type 2 diabetes mellitus in 2 groups each group 50 patients, each group 30 males, and 20 females,35 patients with type 2 diabetes and 15 patients type 1 diabetes all have diabetic peripheral neuropathy, the second group is considered as control.